Touchscreen-based Cognitive Tests in Healthy Volunteers

Brief Summary

This phase Ib study aims to evaluate applicability of touchscreen-based cognitive test battery for assessment of ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers. Additionally, the study aims to assess whether ketamine-induced cognitive deficits are reversed by modafinil using touchscreen-based test battery for testing of cognition.

Intervention / Treatment

  • Drug: Ketamine 0.58
  • Drug: Ketamine 0.31
  • Drug: Modafinil
  • Drug: Placebo for ketamine
  • Drug: Placebo for modafinil

Condition or Disease

  • Cognitive Symptom
  • Schizophrenia

Phase

Study Design

Study type: Interventional
Status: Unknown status
Study results: No Results Available
Age: 20 Years to 40 Years   (Adult)
Enrollment: 16 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Mar 12, 2018
Primary Completion: May 16, 2018
Completion Date: Dec 31, 2019
Study First Posted: Mar 19, 2018
Results First Posted: Aug 31, 2020
Last Updated: Oct 16, 2018

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers are measured by using touchscreen-based cognitive tests. In addition, the study aims to assess whether ketamine-induced cognitive deficits detected by touchscreen-based cognitive tests are reversed by modafinil.

Eligibility Criteria

Sex: Male
Minimum Age: 20
Maximum Age: 40

More Details

NCT Number: NCT03469089
Other IDs: REVISE28347|2017-004455-22
Study URL: https://ClinicalTrials.gov/show/NCT03469089
Last updated: Jun 17, 2022